What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.”In the company’s words, NCT06552416 on ClinicalTrials.gov
- Tested for
- Acute Myeloid Leukemia, in Relapse, MDS
- Main trialPhase 1
- “This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \</= 10% blasts following treatment with an HMA-based therapy.”In the company’s words, NCT06552416 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia, in Relapse
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up1
- Sep 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Sep 2029 | Safety of MT-401-OTS in Patients With Relapsed AML or MDS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026